We are eager to out-license our biotechnologies to mRNA players for the development of mRNA vaccines and therapies, as well as cell therapies (iPS, CAR-T cells and CAR-NK cells) and gene editing.
Last news
OST Group becomes a shareholder in July 2019
posted July 08, 2019
Read More
